Dare Bioscience, Inc.
Dare Bioscience, Inc. is a women’s health biopharmaceutical company developing and commercializing proprietary products across contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company is shifting from a pure development model toward a capital-efficient commercialization model that combines late-stage R&D with near-term revenue opportunities through Section 503B compounded products and consumer health offerings.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes XACIATO and planned Section 503B/consumer health offerings such as DARE to PLAY Sildenafil Cream and DARE to RESTORE.
Includes Ovaprene and DARE-HRT1, which are being advanced toward clinical and commercial milestones.
Includes DARE-VVA1, DARE-HPV and other pipeline assets still in development.
Programs supported by non-dilutive grants, including work tied to DARE-LARC1, Ovaprene and DARE-HPV.
Customers
Dare’s direct customers are healthcare providers, outsourcing facilities, telehealth partners, and third-party commercial partners that help bring its products to market. End users are women seeking solutions in contraception, sexual health, vaginal health, menopause, and related conditions, with some products intended for prescription use and others for consumer health channels.
Prescribe or recommend products such as Sildenafil Cream, XACIATO and future pipeline therapies because they address unmet women’s health needs.
Help market and distribute non-prescription products like DARE to RESTORE and support direct-to-consumer awareness.
Manufacture and dispense compounded products under the company’s Section 503B strategy.
Buy or use the products for contraception, sexual health, vaginal health, menopause and related conditions.
Provide non-dilutive funding, development support, or commercialization access for specific programs.
Strategy
Dare is pursuing a capital-efficient transition from a development-stage biotech into a company with near-term commercial products and a broader women’s health portfolio. Its strategy is to use third-party manufacturing, strategic partnerships and targeted digital/provider marketing to avoid building a large internal sales force while still creating a commercial platform for future pipeline assets.
Creates initial revenue and market presence without building a full sales infrastructure.
The company lacks internal sales and distribution capabilities, so partnerships reduce fixed costs and execution risk.
Clinical progress supports future FDA-approved products and longer-term value creation.
Management wants commercial and grant funding to help fund operations and reduce financing pressure.
Geography
The company is headquartered in the United States and its near-term commercial plans are centered on the U.S. market. It sources some vaginal probiotics from Europe for its consumer health strategy, but the core development, regulatory and commercialization work is U.S.-focused.
Risks
The company remains highly dependent on external capital, clinical success and execution of a still-developing commercialization model. Its business also carries typical biotech risks around regulatory approval, product launch timing, manufacturing transfer, and the possibility that near-term revenue remains immaterial or delayed.
- Insufficient capital to fund operations and developmentImpact: CriticalLikelihood: High
The company states it may need to delay, scale back, or cease programs if it cannot raise funds on acceptable terms.
Exposure - Nasdaq listing complianceImpact: HighLikelihood: High
Failure to meet continued listing standards could impair liquidity and access to capital.
Exposure: Equity financing and market confidence
- Clinical development and regulatory approval riskImpact: HighLikelihood: High
Pipeline value depends on successful IND filings, clinical studies and FDA outcomes.
Exposure - Commercial launch and adoption riskImpact: High
Near-term products may not generate meaningful revenue if provider adoption or consumer demand is weak.
Exposure - Dependence on third partiesImpact: Medium
The company relies on outsourcing facilities, collaborators and marketing partners rather than owned infrastructure.
Exposure
Accounting
Judgemental itemsCash received under grants is restricted to specific project costs and can create deferred liabilities until spent.
Impact: Affects cash, liabilities and the timing of R&D expense recognition
Management explicitly notes dependence on future capital to continue operations.
Impact: Can affect disclosure, valuation assumptions and investor risk perception
Commercial or development milestones may trigger payments to licensors or collaborators.
Impact: Can create lumpy operating expenses or accrued liabilities
Personnel costs include stock compensation in both R&D and G&A.
Impact: Impacts reported operating loss and non-cash expense trends
Similar listed companies
Publicly listed companies with a comparable business focus.
Evofem Biosciences, Inc.
EVFM · Pharmaceutical Preparations
Pure Bioscience, Inc.
PURE · Miscellaneous Chemical Products
Forte Biosciences, Inc.
Pharmaceutical Preparations
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026